Holen Sie sich die Stockscreener-App
33.44
4.60%
1.48
Schlusskurs vom Vortag:
$31.96
Offen:
$32.28
24-Stunden-Volumen:
273.77K
Relative Volume:
0.23
Marktkapitalisierung:
$1.91B
Einnahmen:
$199.89M
Nettoeinkommen (Verlust:
$52.48M
KGV:
39.34
EPS:
0.85
Netto-Cashflow:
$61.15M
1W Leistung:
+1.36%
1M Leistung:
+13.94%
6M Leistung:
+188.69%
1J Leistung:
+186.22%
1-Tages-Spanne:
$31.74
$33.90
1-Wochen-Bereich:
$31.50
$34.05
52-Wochen-Spanne:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.40 | 1.83B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.50 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.30 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
410.44 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
853.84 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.75 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Inflation Data: Is Stoke Therapeutics Inc. stock a buy in volatile marketsRate Hike & Weekly Consistent Profit Watchlists - Улправда
Aug Swings: What valuation multiples suggest for Stoke Therapeutics Inc stockQuarterly Portfolio Summary & Technical Buy Zone Confirmation - moha.gov.vn
Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Is Stoke Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Recap & Verified Momentum Stock Watchlist - Улправда
Stoke Therapeutics (FRA:0GT) EV-to-OCF : 25.91 (As of Dec. 19, 2025) - GuruFocus
Analyst Confidence Surges for Stoke Therapeutics Following Key Data - AD HOC NEWS
Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117% - MSN
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright - Investing.com India
HC Wainwright & Co. Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Stoke Therapeutics Inc diskutieren - sharewise.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright - MarketBeat
STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus
Stoke Therapeutics Earnings Notes - Trefis
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Dir Kaye Sells 13,430 ($433.4K) Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Officer Allan Files To Sell 3,978 Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics highlights Zorevunersen’s potential at epilepsy meeting - MSN
Biogen, Stoke Therapeutics announce data presentations for zorevunersen - MSN
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $267,723.36 in Stock - MarketBeat
Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $52,355.52 in Stock - MarketBeat
Allan Jonathan of Stoke Therapeutics sells $306k in shares By Investing.com - Investing.com South Africa
Allan Jonathan of Stoke Therapeutics sells $306k in shares - Investing.com
Stoke Therapeutics Executives Conduct Multiple Stock Sales - TradingView — Track All Markets
Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com UK
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Fly 36% But Investors Aren't Buying For Growth - 富途牛牛
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Zorevunersen shows promise for Dravet syndrome in long-term data By Investing.com - Investing.com South Africa
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting - TipRanks
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):